Logo

GNFT

Genfit S.A.

GNFT

Genfit S.A. • NASDAQ
$4.68 ▲ 4.00% (+0.18)
Market Cap $233.05 M
52w High $4.93
52w Low $2.55
Dividend Yield 0%
P/E -5.2
Volume 2.01K
Outstanding Shares 49.80M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $35.535M ▲ $35.459M ▼ $-9.956M ▲ -28.017% ▲ $-0.2 ▲ $955K ▲
Q4-2024 $5.9M ▼ $37.531M ▲ $-28.804M ▼ -488.203% ▼ $-0.58 ▼ $-24.212M ▼
Q2-2024 $61.102M ▲ $29.88M ▲ $30.311M ▲ 49.607% ▲ $0.61 ▲ $32.008M ▲
Q4-2023 $14.265M ▲ $26.652M ▼ $-8.04M ▲ -56.362% ▲ $-0.16 ▲ $-10.152M ▲
Q2-2023 $11.482M $34.387M $-20.854M -181.623% $-0.42 $-20.849M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $107.511M ▲ $216.683M ▲ $164.211M ▲ $52.472M ▼
Q4-2024 $81.788M ▲ $151.424M ▼ $82.2M ▼ $69.224M ▼
Q2-2024 $61.645M ▼ $194.777M ▲ $97.414M ▼ $97.363M ▲
Q4-2023 $77.789M ▼ $173.872M ▼ $105.921M ▼ $67.951M ▼
Q2-2023 $111.826M $193.905M $119.385M $74.52M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-9.956M ▲ $-30.102M ▼ $-3.219M ▼ $59.287M ▲ $25.723M ▲ $-31.156M ▼
Q4-2024 $-28.804M ▼ $26.925M ▲ $-352K ▲ $-6.535M ▼ $-61.645M ▼ $26.683M ▲
Q2-2024 $30.311M ▲ $-11.187M ▲ $-687K ▼ $-4.225M ▼ $61.645M ▲ $-11.924M ▲
Q4-2023 $-28.894M ▼ $-30.355M ▼ $-448K ▼ $-3.334M ▼ $-34.037M ▼ $-30.769M ▼
Q2-2023 $-20.854M $-25.843M $2.682M $-995K $-24.175M $-27.843M

Five-Year Company Overview

Income Statement

Income Statement Genfit’s income statement still looks like that of an emerging biotech rather than a mature commercial company. Revenue over the past few years has been very small and quite volatile, reflecting milestone and partnership payments more than steady product sales. Profitability has swung from meaningful losses to a couple of years roughly around break-even or modest profit, which is typical when deal payments or one‑off items land in a given year. The recent approval and launch of Iqirvo® marks a turning point, but it is still early: the current figures show a business in transition, with no clear track record yet of stable, recurring commercial earnings. Investors should expect continued earnings volatility as launch costs, R&D spending, and irregular milestone or royalty income move around from year to year.

Balance Sheet

Balance Sheet The balance sheet has strengthened compared with a few years ago. The company moved from a stressed equity position earlier in the period to having a positive capital base, helped by partnerships and financing deals rather than heavy new share issues. Cash represents a significant share of total assets, which is important for a biotech still investing heavily in clinical programs. Debt is present but not extreme relative to the size of the company, and it has come down from earlier, more leveraged levels. Overall, the balance sheet now looks more resilient than in the past, but it still depends on careful cash management and continued access to non-dilutive funding.

Cash Flow

Cash Flow Cash flow tells the story of a company that has been burning cash for R&D, occasionally offset by large inflows from partnerships. Operating cash flow was negative in several years as clinical development spending outweighed incoming payments, with one or two years of positive cash flow when deal-related cash arrived. Capital expenditure is very light, so free cash flow largely mirrors operating cash flow. Recent years show a move toward more balanced cash usage, and the royalty financing deal with HCRx adds extra breathing room by front‑loading some future economics. Even so, the business remains dependent on successful product launches and pipeline progress to eventually generate self-sustaining cash flows.

Competitive Edge

Competitive Edge Genfit’s competitive position is built around a focused leadership in severe liver diseases, rather than trying to compete broadly across all of biotechnology. The approval of Iqirvo® in PBC gives it a differentiated, first‑in‑class therapy in a rare disease with meaningful unmet need, while the Ipsen partnership provides global commercial muscle that Genfit could not easily build alone. Its diagnostic platform (NIS2+™) adds an additional angle in metabolic liver disease, offering a non‑invasive way to identify high‑risk patients. In ACLF, Genfit is trying to be an early mover in an area with no approved treatments, which could be powerful if the science works but also carries high clinical risk. A large patent estate and deep liver‑disease expertise help protect its niche, but competition from larger pharma and evolving standards of care remain important threats.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Genfit’s story. The company has already turned one long‑running R&D program into an approved drug (Iqirvo®), which supports the credibility of its scientific and regulatory capabilities. Its pipeline is diversified within liver and related rare diseases: multiple ACLF candidates with different mechanisms, a program in bile duct cancer, and work in rare metabolic disorders. This gives several shots on goal, but also locks the company into high, ongoing R&D spending and significant scientific uncertainty. Success depends on turning today’s promising clinical signals into clear, late‑stage data and regulatory approvals. The strategy is high risk, high reward, and execution in the next few years will be critical in determining whether the current pipeline can replicate the success of elafibranor.

Summary

Genfit today looks like a transition‑stage biotech moving from pure R&D into an early commercial model anchored by Iqirvo® and supported by royalties and milestone payments. Financially, it has reduced past balance‑sheet stress and improved its cash outlook, but its income statement and cash flows remain volatile and heavily influenced by deal timing. Strategically, it occupies an attractive but demanding niche in serious liver diseases, with a genuine first‑in‑class product, differentiated diagnostics, and a pipeline aimed at areas with very limited existing treatments. The main opportunities lie in scaling Iqirvo® with Ipsen and successfully advancing the ACLF and other rare‑disease programs. The main risks are the usual biotech challenges: clinical failures, regulatory setbacks, slower‑than‑expected uptake of the approved drug, and ongoing dependence on external financing and partners. Overall, this is a focused, innovation‑driven story whose future will be determined far more by scientific and commercial execution than by its recent historical financials.

NEWS

November 27, 2025 · 12:00 PM UTC

GENFIT Announces Appointment of new Chief Medical Officer

Read more

November 20, 2025 · 12:10 PM UTC

GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update

Read more

November 20, 2025 · 12:00 PM UTC

GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market

Read more

November 10, 2025 · 1:45 AM UTC

GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF

Read more

November 10, 2025 · 1:30 AM UTC

GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025

Read more